AVTxx

AVTxx is a placeholder designation for undisclosed biosimilar candidates developed through a partnership between **MiGenTra** and **Alvotech**. MiGenTra, a joint venture between Egypt's Minapharm Pharmaceuticals and Germany's ProBioGen, focuses on providing affordable biologics to the African and Middle Eastern markets. Alvotech, a specialist in biosimilar development, provides the technical platform for these assets. As of the current pipeline status, specific targets, modalities, and therapeutic indications for the AVTxx candidates have not been publicly disclosed, though they are part of a broader effort to expand access to high-quality biopharmaceuticals in emerging markets.